Description
Tesamorelin 10mg — Product Identity and Format
Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH 1-44) incorporating a trans-3-hexenoic acid modification at the N-terminus (trans-3-hexenoyl-Tyr1-GHRH 1-44).
Core Research supplies tesamorelin as a lyophilised research-grade material, verified by reverse-phase high-performance liquid chromatography (RP-HPLC) to a minimum purity of ≥99.0% and with identity confirmed by electrospray ionisation mass spectrometry (ESI-MS). Each 10mg vial is accompanied by a batch-specific Certificate of Analysis. This product is supplied for in vitro and pre-clinical research use only and is not the authorised medicinal product tesamorelin acetate (Egrifta®), which is a prescription medicine licensed for a specific clinical indication.
Analytical Specification
| Parameter | Specification |
|---|---|
| INN / Common Name | Tesamorelin |
| Structural Description | Trans-3-hexenoyl-Tyr1-GHRH(1-44)-NH2 — N-terminally modified 44-amino-acid GHRH analogue |
| CAS Number | 218949-48-9 (free acid) | 901758-09-6 (acetate salt) |
| Molecular Formula | C221H366N72O67S (free acid) |
| Molecular Weight | 5,135.77 Da (free acid) |
| Salt Form | Acetate (research-grade lyophilised material) |
| Physical Form | White to off-white lyophilised powder |
| Purity (RP-HPLC) | ≥99.0% by area normalisation (C18, UV 220 nm) |
| Identity Confirmation | ESI-MS (observed vs. theoretical monoisotopic mass) |
| Endotoxin | <1.0 EU/mg (LAL kinetic turbidimetric) |
| Fill per Vial | 10mg |
| Sterility | Non-sterile lyophilised research material |
Analytical Note — Core Research Quality Team
Tesamorelin is a 44-amino-acid peptide with a molecular weight of approximately 5,136 Da. At this size, ESI-MS identity confirmation is performed using multiply-charged ions ([M+5H]5+, [M+6H]6+, [M+7H]7+) rather than the singly-charged ions used for smaller peptides. The N-terminal trans-3-hexenoyl modification adds a characteristic mass increment of 96.06 Da relative to the unmodified Tyr1-GHRH sequence, which is confirmed in the ESI-MS spectrum. Batch-specific CoA documents are available through the CoA Portal.
Structural Identity and DPP-IV Resistance
Native GHRH (1-44) is rapidly inactivated in plasma by dipeptidyl peptidase IV (DPP-IV), which cleaves the Tyr1-Ala2 bond to produce the inactive fragment GHRH(3-44).
This structural approach — N-terminal fatty acid or alkenyl modification to confer DPP-IV resistance — is distinct from the strategy used in CJC-1295 No DAC (Mod-GRF 1-29), which achieves DPP-IV resistance through amino acid substitution at position 2 (Ala2→D-Ala) and uses only the first 29 residues of GHRH.
Tesamorelin vs Tesamorelin Acetate (Egrifta®) — Research vs Medicinal Product
The authorised medicinal product tesamorelin acetate (Egrifta®, Theratechnologies) is a prescription medicine licensed by the FDA for a specific clinical indication. The Core Research supply is a research-grade lyophilised material supplied under Research Use Only conditions. These are distinct entities: the medicinal product is manufactured to GMP standards, is subject to regulatory oversight, and is intended for administration to patients under medical supervision. The Core Research research material is not a medicinal product, is not manufactured to GMP, and must not be used in humans or animals.
Storage and Transport
| Condition | Specification |
|---|---|
| Long-Term Storage (lyophilised, sealed) | −20°C, protected from light and moisture |
| Stability Period | Stated on the batch-specific CoA |
| Transit | Ambient; cold-chain packaging included |
Note: Reconstituted solution storage, solvent selection, working concentration, and stability period guidance are not provided, consistent with Core Research’s Research Use Only supply policy. Researchers should refer to their institutional SOPs and the published literature for handling reconstituted peptide solutions.
Regulatory Status and Compliance
Tesamorelin (as the acetate salt, Egrifta®) holds regulatory approval as a prescription medicine in specific jurisdictions for a specific clinical indication. The Core Research supply is a research-grade lyophilised material and is not an authorised medicinal product. Tesamorelin appears on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is therefore prohibited in competitive sport. All orders are subject to our Terms and Conditions and Research Use Policy.
Batch Documentation
Every batch of Tesamorelin 10mg dispatched by Core Research is accompanied by a batch-specific Certificate of Analysis confirming RP-HPLC purity (≥99.0%), ESI-MS identity, and endotoxin result. CoA documents are available via the Certificate of Analysis Portal. For further information on our analytical methodology, refer to the guide on HPLC Purity in Peptide Research.
Research context
The published literature on this material is summarised in the laboratory guides linked below. This record describes the material as supplied: identity, format, analytics, storage and documentation. It does not describe effects, and none should be inferred from the catalogue category.
For Research Use Only
Tesamorelin is supplied exclusively for in vitro laboratory research. It is not a medicinal product, is not approved for any therapeutic indication in this supply format, and must not be administered to humans or animals. No dosing, reconstitution, or administration guidance is provided.
